New appointment at NormOxys
This article was originally published in Scrip
Executive Summary
NormOxys, a US-based biotechnology company developing a class of small-molecule drugs which enhance the body’s ability to deliver oxygen to diseased tissues, has appointed Dr John Hey senior vice-president of preclinical and early development. In the role, he will be responsible for the drug discovery and preclinical drug development activities for the company's platform of novel oxyren compounds, as well as all preclinical research. Dr Hey, who has than 20 years' drug discovery and development experience, joins from CoMentis, where he served as senior vice-president of discovery and preclinical drug development.